New data show that RAD001 (everolimus) may provide a new treatment option for patients with advanced kidney cancer who have failed standard therapies.
New data show that RAD001 (everolimus) may provide a new treatment option for patients with advanced kidney cancer who have failed standard therapies.
RAD001 significantly extended the time without tumor growth from 1.9 to 4 months and reduced the risk of cancer progression by 70% (HR=0.30; 95% CI: 0.22-0.40; p<.0001), according to interim study findings presented at the American Society of Clinical Oncology annual meeting in Chicago.
Earlier this year, an independent data monitoring committee stopped the REnal Cell cancer treatment of Oral RAD001 given Daily (RECORD-1) trial after interim results showed that patients receiving RAD001 experienced a significantly longer time without their cancer worsening than patients receiving placebo did. The trial included patients whose cancer had stopped responding to approved treatments for renal cell carcinoma.
RAD001 is a once-daily oral therapy that may offer a new approach to cancer treatment by continuously inhibiting the mTOR protein, a central regulator of tumor cell division and blood vessel growth in cancer cells.
“This is the first study to show clinical benefit in patients with advanced kidney cancer who have experienced treatment failure with the most commonly used first-line therapies,” said principal investigator Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center in New York. “The results show RAD001 extended progression-free survival in patients, regardless of their prior treatments, risk status, age, or gender.”
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.